Drug intelligence / Profile preview

molnupiravir + nirmatrelvir + ritonavir

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of three antiviral medications studied for potential synergistic effects against SARS-CoV-2. Molnupiravir is a nucleoside analogue that inhibits viral replication by introducing errors into the viral RNA. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor that blocks viral replication. Ritonavir is a pharmacologic booster that slows the breakdown of nirmatrelvir. While molnupiravir and nirmatrelvir/ritonavir are each approved as separate treatments for COVID-19, they are not typically administered together as a standard combination therapy.

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)Mpro (3C-like proteinase of SARS-CoV-2)CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on molnupiravir + nirmatrelvir + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on molnupiravir + nirmatrelvir + ritonavir.

Explore the full profile